WATERTOWN, MASSACHUSETTS, April 28, 2026
Kestrel Therapeutics Inc. has announced a major clinical milestone with the first patient dosed in its Phase 1 trial of KST-6051, a next-generation pan-KRAS inhibitor designed to target a broad spectrum of KRAS-driven cancers. The study evaluates the investigational oral therapy in patients with advanced or metastatic solid tumors harboring KRAS mutations, marking a critical step forward in addressing one of the most challenging targets in oncology. In parallel, Kestrel has entered into a strategic agreement with AbbVie, which includes an exclusive option to acquire the company based on development milestones, with a potential deal value of up to $1.45 billion, highlighting strong industry confidence in the program.
Novel Pan-KRAS Inhibitor Targets Broad Cancer Types
The investigational therapy KST-6051 is designed as a best-in-class small-molecule inhibitor that binds directly to KRAS in both its active (GTP-bound) and inactive (GDP-bound) states, enabling comprehensive pathway suppression. Unlike earlier KRAS inhibitors that target specific mutations, KST-6051 aims to provide broad coverage across multiple KRAS-driven malignancies, including pancreatic cancer, colorectal cancer, and non-small cell lung cancer.
Importantly, the molecule selectively spares HRAS and NRAS, potentially reducing toxicity risks associated with non-selective inhibition. Preclinical data have demonstrated robust anti-tumor activity and favorable tolerability, positioning the drug as a promising candidate in the evolving field of targeted oncology therapies.
Phase 1 Trial Design and Clinical Objectives
Advertisement
The ongoing Phase 1 study, known as FALCON (KST-6051-101), is a multicenter, open-label, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of KST-6051. The trial will enroll patients with advanced metastatic solid tumors who have progressed after standard therapies, addressing a population with significant unmet medical need.
The study includes a dose-escalation phase followed by expansion cohorts in selected tumor types, aiming to determine the recommended dose for further clinical development. Secondary endpoints include assessments of pharmacodynamics and early signals of efficacy, which will be critical in guiding future Phase 2 and Phase 3 trials.
Strategic Collaboration with AbbVie Strengthens Pipeline
The partnership between Kestrel and AbbVie represents a strategic collaboration to accelerate oncology innovation, combining Kestrel’s expertise in KRAS-targeted drug discovery with AbbVie’s global development and commercialization capabilities. Under the agreement, AbbVie will provide financial support for the KST-6051 program and retains an exclusive option to acquire Kestrel upon achieving predefined milestones. This collaboration reflects a broader industry trend toward strategic alliances and milestone-based acquisitions in early-stage oncology development.
From a GxP perspective, the program demonstrates strong adherence to Good Clinical Practice (GCP) through its rigorous trial design and execution, with future considerations for Good Manufacturing Practice (GMP) as the therapy advances toward commercialization. With KRAS mutations present in approximately 20% of all cancers, KST-6051 has the potential to transform treatment paradigms and significantly improve outcomes for patients with limited therapeutic options.
Source: Kestrel Therapeutics, AbbVie press release
